- Introduction to Clinical Research Training
- Medical Education
- United Kingdom Clinical Scholars Research Training
- Vanderbilt Hall
- Financial Aid
- Office of the Registrar
- Campus Planning and Facilities
- Ombuds Office
- Committee on Microbiological Safety
- Human Resources
- HMS Foundation Funds
- Office for Academic and Clinical Affairs
- Joint Committee on the Status of Women
- The Academy
- Global Health Research Core
- Global Clinical Scholars Research Training Program
- HMA Standing Committee on Animals
- Office of Research Compliance
- Global & Community Health
- Harvard Medical School Event Calendar
- Contact @HMS
- Office of Diversity RIA Program
- The Dean's Perspective
- Department of Pathology
- Harvard Mahoney Neuroscience Institute
- OHRA Home
- Office of Research Subject Protection
- Tools and Technology
- Alumni Association
- Cancer Biology & Therapeutics Program
- Celiac Program
- Department of Medicine
- HMS Community Values Initiative
- HMS Information Technology
- HMS TransMed Program
- Introduction to the Practice of American Medicine
- Office of Communications & External Relations
- Office of Global Education
- Shenzhen-HMS Initiative in International Education
- South American Clinical Research Training
- test page
- Safety Quality and Informatics Leadership
- Human Resources
- Jobs @ HMS
- Contact us
- Dental Medicine
- Harvard University
November 6, 2013
A fine-grained scan of DNA in lung cancer cells has revealed a gene fusion—a forced merger of two normally separate genes—that spurs the cells to divide rapidly, scientists at Harvard Medical School, Dana-Farber Cancer Institute and the University of Colorado report in a new paper in the journal Nature Medicine. Treating the cells with a compound that blocks a protein encoded by one of those genes—NTRK1—caused the cells to die.
The finding suggests that the fusion of NTRK1 to other genes fuels the growth of some lung adenocarcinomas (a form of non-small cell lung cancer), and that drugs that target NTRK1’s protein product could be effective in patients whose lung tumors harbor such fusions.
“Treatment with targeted therapies is now superior to standard chemotherapy for many patients with lung cancers that harbor genetic changes, including those with fusions involving the gene ALK,” said Pasi A. Jänne, HMS associate professor of medicine at Brigham and Women’s Hospital and Dana-Farber, and senior co-author of the paper. “We know of several other genes that are fused in lung cancer and that offer attractive targets for new therapies. Our discovery places lung adenocarcinomas with NTRK1 fusions squarely within that group.”
In the study, researchers performed next-generation DNA sequencing tests, which read the individual elements of the genetic code over long stretches of chromosomes, on tumor samples from 36 patients with lung adenocarcinomas whose tumors did not contain any previously known genetic alterations that could be found with standard clinical tests. In two of those samples—both from women who had never smoked—investigators found that a key region of the NTRK1 gene had become fused to normally distant genes (to the gene MPRIP in one patient; and the gene CD74 in the other).
NTRK1 holds the blueprint for a protein called TRKA, which dangles from the surface of cells and receives growth signals from other cells. The binding of NTRK1 to other genes causes TRKA to issue cell-growth orders on its own, without being prompted by outside signals.
In the laboratory, investigators mixed NTRK1-inhibiting agents into lung adenocarcinoma cells harboring NTRK1 fusions. The result was a dampening of TRKA’s activity and the death of the cancer cells.
Investigators then designed a new test using fluorescence in situ hybridization (FISH) to detect NTRK1 fusions and tested an additional 56 tumor samples. In total, 3 of 91 tumor samples that had no other sign of cancer-causing genetic abnormalities had fusions involving NTRK1.
“These findings suggest that in a few percent of lung adenocarcinoma patients—in whose cancer cells we had previously been able to find no genetic abnormality—tumor growth is driven by a fusion involving NTRK1,” Jänne said. “Given that lung cancer is a common cancer, even a few percent is significant and translates into a large number of patients. Our findings suggest that targeted therapies may be effective for this subset of lung cancer patients.”
“This is still preclinical work,” said Robert Doebele of the University of Colorado Cancer Center and co-author on the paper, “but it’s the first—and maybe even second and third—important step toward picking off another subset of lung cancer with a treatment targeted to the disease’s specific genetic weaknesses.”
The research was supported by the Colorado Bioscience Discovery Evaluation Grant Program, the National Institutes of Health, and the Boettcher Foundation’s Webb-Waring Biomedical Research Program, the Cammarata Family Foundation Research Fund, and the Nirenberg Fellowship at Dana-Farber.
Adapted from a Dana-Farber Cancer Institute news release.